Healthcare
ViaDerma, Inc.(VDRM)
Live Price
Offline$0.0004
+0.00% today
1Y Change
+33.33%
Window
Jun 20, 2025 β Jun 12, 2026
- Market Cap
- β
- Revenue Growth
- +11.1%
- EPS Growth
- -100.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars Β· Jun 20, 2025 β Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ViaDerma, Inc. (VDRM) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 33.3% across the available one-year price window (Jun 20, 2025 β Jun 12, 2026). Baseline metrics include revenue growth of +11.1%, EPS growth of -100.0%, a dividend yield of 0.0%. What stands out right now is revenue +11.1%, EPS -100.0%, free cash flow +111.7% with operating margin 30.9% and ROIC 41.5%. Valuation already assumes a fairly strong business story at P/E 115.0 and price/sales 0.8. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines VDRM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+11.1% vs +7.6% peer median
Operating Margin
Above sector median
+30.9% vs +19.4% peer median
P/E
Above sector median
115.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Oct 1, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +11.1% and EPS is at -100.0%, with operating margin around 30.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -16.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Oct 1, 2025 | β | +0.0% | -50.0% | +0.0% |
2025 Jun 4, 2025 | β | +0.0% | +0.0% | +133.3% |
2025 Apr 29, 2025 | β | +0.0% | +0.0% | +133.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VDRM
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
VDRM Max Drawdown
-94.12%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VDRM and SPY.
Company Overview
ViaDerma, Inc.
Other OTC
ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as DΓ©cor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California.
- Leadership
- Christopher A Otiko
- IPO Date
- Oct 31, 2014
- Employees
- 75
- Street Address
- 4640 Admiralty Way
- Mailing
- Marina del Rey, CA, 90292
- Region
- Marina del Rey, CA, US
- Reporting Currency
- USD
- Investor Line
- 310 496 5744
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 115.0
- EV/EBITDA
- 10.0
- Price/Sales
- 0.8
- Price/Book
- 3.8
Growth
- Revenue
- +11.1%
- EPS
- -100.0%
- Free Cash Flow
- +111.7%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- 30.9%
- Net Margin
- 0.7%
- ROE
- -0.5%
- ROIC
- 41.5%
Balance Sheet
- Debt/Equity
- 2.62
- Current Ratio
- 1.10
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.